





AUTHORISED PAEDIATRIC CLINICAL TRIALS IN SPAIN



Maria Jesus Fernandez Cortizo, (AEMPS, PDCO)

In collaboration with: Teresa Llácer Delicado (AEMPS)

Acknowledgements: Clinical Trial Unit (AEMPS)

The views expressed are personal and do not necessarily represent the point of view of the AEMPS, nor those of the Paediatric Committee (PDCO) of the EMA.







CONTENT

□ Analysis of clinical trials (CT) with medicinal products including the paediatric population that have been authorised in 2017 and 2018 in our country.

- AEMPS CT database (ECMI, Ensayos Clínicos con Medicamentos en Investigación)
- Spanish Registry of Clinical Trials ("REec") in which clinical trials are uploaded once authorised by AEMPS. Offers the most updated information. https://reec.aemps.es/reec/public/web.html
- AEMPS 2017 Annual Report

https://www.aemps.gob.es/home.html

Limitations:

- ✓ CT that are rejected
- ✓ CT prematurely ended or those which never start









PAEDIATRIC CT

Adults G **Paediatric** population B Paediatriconly population










AUTHORISED CT (n)











AEMPS 2017 Annual report

Percentage of authorised CT per AGE GROUPS

TABLA	Porcentaje de	de ensayos clínicos por la edad					
ENSAYOS CLÍ EDADES	NICOS POR	2013	2014	2015	2016	2017	
Adults		90%	91%	92%	93%	92,9%	
Elderly		69%	72%	73%	74%	72,3%	
Paediatric population		13%	13%	12%	13%	14%	

Age categories collected as indicated in the CT application

- Intrauterine
- **Preterm newborns** (<37 weeks GA)
- **Term newborns** (≥37 weeks GA)
- **Infants and toddlers** (28 days-23 months)
- **Children** (2-11 years)
- Adolescents (12-17 years)




















Paediatric CT per AGE GROUP (n)












Paediatric-only CT per AGE GROUP (n)












Paediatric CT included in a PIP (n,%)



^{*}Information about PIP as indicated in the CT application











CT by type of SPONSOR (n, %)






2018








CT per THERAPEUTIC AREA (MedDRA)











SITES INVOLVED per main TA

Oncology

- 35 sites in 10 AC (2018)
- 45 sites in 12 AC (2017)

Respiratory tract diseases

- 22 sites in 5 AC (2018)
- 44 sites in 5 AC (2017)

Haematology

- 10 sites in 5 AC (2018)
- 20 sites in 6 AC (2017)

Infectious diseases

56 sites in 9 AC (2018) 52 sites in 10 AC (2017)

AC: Autonomous Community










Sites and locations involved in paediatric CT



Total number of sites involved in CT enrolling paediatric population: 113









CONCLUSIONS

- The percentage of CT that include paediatric population remains below 15% of the global number authorised. Most of them are mixed trials (enrolling paediatric and adult subjects).
- The age groups mostly included in the CT authorised in Spain were adolescents and children.
- The **main therapeutic areas** investigated in paediatric CT were oncology, respiratory tract diseases, haematology, neurology and infectious diseases.

















European Medicines Agency and European Commission (DG Health and Food Safety) action plan on paediatrics

2. Strengthening of cooperation of decision makers

	Action	Objectives	Status (July 2018)	Deadline
1	Establish framework for exchange of information between the EMA/PDCO and the Clinical Trial Facilitation Group (CTFG) as well as ethics committees	To improve dialogue between EMA/PDCO and clinical trial assessors and facilitate mutual understanding of the interplay between assessment of PIPs and of clinical trials.	In progress.	12/2020










AEMPS



Information about all authorized CT with medicinal products

https://reec.aemps.es/reec/public/web.html



Office for support of Innovation and knowledge of medicinal products

<u>innov spain@aemps.es</u>



Independent Clinical Research Support Office

https://www.aemps.gob.es/investigacionClinica/medicamentos/oficinApoyo.htm





